Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the antiviral efficacy, pharmacokinetics, and tolerability of 200 mg BILN
2061 ZW in a polyethylene glycol 400 (PEG 400: ethanol) drinking solution given orally for
two days bid to patients with cirrhosis and chronic Hepatitis C Virus (HCV) infection